News >

Questions Remain With CAR-T's, Checkpoints in Hematologic Malignancies

Chelsea LoCascio
Published: Monday, Nov 13, 2017

ALeo I. Gordon MD

Leo I. Gordon MD
Despite major progress with chimeric antigen receptor (CAR) T-cell therapy and immune checkpoint inhibitors in hematologic malignancies, questions remain regarding the use of these therapies in this landscape, according to Leo I. Gordon, MD.

on Hematologic Malignancies, Gordon, a professor of medicine at Feinberg School of Medicine, Northwestern University, and chair of the meeting, discussed promising advances and lingering challenges with novel treatments for patients with hematologic malignancies.

OncLive: There have a handful of recent FDA approvals and encouraging clinical trial results across the field of hematologic cancers. What is most notable to mention?

Gordon: In the beginning [of the conference], Dr Olga Frankfurt spoke about acute myeloid leukemia (AML). The highlight there is better understanding of the disease and better understanding of the molecular biology. The big question for AML is, “When will that translate into better outcomes?” We've been struggling with that for years, but Dr Frankfurt had some exciting data. She also spoke about novel clinical trials that are based upon some of the molecular defects that have now been uncovered. We're beginning to make progress in AML.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 3rd Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesNov 29, 20192.0
Advances in™ ALL: The Role of T-Cell Engaging Immunotherapy in Treating Relapsed DiseaseNov 30, 20191.0
Publication Bottom Border
Border Publication